Drug Profile
Rimtuzalcap - Novartis
Alternative Names: CAD-1883Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Cadent Therapeutics; Saniona
- Developer Novartis
- Class Amines; Antiparkinsonians; Cyclohexanes; Fluorinated hydrocarbons; Morpholines; Neuropsychotherapeutics; Pyrazoles; Pyrimidines; Small molecules
- Mechanism of Action Small conductance calcium activated potassium channel modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Essential tremor
- No development reported Spinocerebellar ataxias
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for phase-I development in Spinocerebellar ataxias in USA (PO, Capsule)
- 05 Apr 2021 Novartis withdraws phase II Synchrony-1 trial in Spinocerebellar ataxias in USA (PO) prior to enrolment due to pipeline reassessment (NCT04301284)
- 25 Jan 2021 Cadent Therapeutics has been acquired and merged into Novartis